Indication
Mycodapt-S™ is an antimetabolite immunosuppressant indicated for prophylaxis of organ rejection in adult kidney-transplant recipients and in paediatric patients aged 5 years or older who are at least 6 months post kidney transplant. Often used in combination with cyclosporine or tacrolimus and corticosteroids.
Mechanism of action
Mycophenolic acid (the active metabolite) is a selective, reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme of de-novo guanosine nucleotide synthesis. T and B lymphocytes are uniquely dependent on this pathway, giving the molecule its targeted immunosuppressive effect with relative sparing of other cell lines.
Strengths
- •360 mg delayed-release tablet
Composition
Each Mycodapt-S™ delayed-release tablet contains Mycophenolate Sodium 360 mg.
Presentation
Alu-alu foil pack of 10 delayed-release tablets in one strip, six strips in a box.
For Healthcare Professionals
Adult kidney-transplant dose: 720 mg twice daily (1,440 mg/day total). Paediatric ≥5 years, ≥6 months post-transplant: 400 mg/m² BSA twice daily (max 720 mg twice daily). Take on an empty stomach, at least one hour before or two hours after meals. Tablets must not be crushed or broken - they are delayed-release.
This section is intended for use by registered medical practitioners only. All clinical decisions remain the prescriber's responsibility and should be informed by the current approved product label.
Notes for patients & caregivers
Take whole; do not crush, chew or split. Take at the same times each day on an empty stomach. Speak to your transplant team if you are or might become pregnant before starting therapy.
These notes are for general awareness only and are not a substitute for medical advice. Please follow your treating physician's instructions and the directions on the dispensed product.
Storage
Store below 30°C. Protect from light and moisture.
Important
- • Mycodapt-S™ is a prescription medicine. It must only be used on the advice of a registered medical practitioner.
- • Always refer to the current approved Indian product label / package insert for definitive prescribing information.
- • If you experience any quality or safety concern, please contact us or write to info@vyapitus.com.